Display options
Cite
Malaguarnera G, Pennisi M, Gagliano C, et al. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014;14(5):e11608doi: 10.5812/hepatmon.11608.
Malaguarnera, G., Pennisi, M., Gagliano, C., Vacante, M., Malaguarnera, M., Salomone, S., Drago, F., Bertino, G., Caraci, F., Nunnari, G., & Malaguarnera, M. (2014). Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepatitis monthly, 14(5), e11608. https://doi.org/10.5812/hepatmon.11608
Malaguarnera, Giulia, et al. "Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial." Hepatitis monthly vol. 14,5 (2014): e11608. doi: https://doi.org/10.5812/hepatmon.11608
Malaguarnera G, Pennisi M, Gagliano C, Vacante M, Malaguarnera M, Salomone S, Drago F, Bertino G, Caraci F, Nunnari G, Malaguarnera M. Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. Hepat Mon. 2014 May 05;14(5):e11608. doi: 10.5812/hepatmon.11608. eCollection 2014 May. PMID: 24910702; PMCID: PMC4030263.
Copy Download .nbib Format: NLM
Share it on

Hepat Mon. 2014 May 05;14(5):e11608. doi: 10.5812/hepatmon.11608. eCollection 2014 May.

Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon-α 2b Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial.

Hepatitis monthly

Giulia Malaguarnera, Manuela Pennisi, Caterina Gagliano, Marco Vacante, Michele Malaguarnera, Salvatore Salomone, Filippo Drago, Gaetano Bertino, Filippo Caraci, Giuseppe Nunnari, Mariano Malaguarnera

Affiliations

  1. Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy.
  2. Department of Neurosciences, University of Catania, Catania, Italy.
  3. The Great Senescence Research Center, University of Catania, Catania, Italy.
  4. Department of Clinical and Molecular Biomedicine, Section of Pharmacology and Biochemistry, University of Catania, Catania, Italy ; The Great Senescence Research Center, University of Catania, Catania, Italy.
  5. Department of Internal Medicine and Systemic Diseases, University of Catania, Catania, Italy.
  6. Department of Educational Sciences, University of Catania, Catania, Italy ; Institute for Research on Mental Retardation and Brain Aging, Troina, Italy.
  7. Department of Clinical and Molecular Biomedicine, Division of Infectious Diseases, University of Catania, Catania, Italy.

PMID: 24910702 PMCID: PMC4030263 DOI: 10.5812/hepatmon.11608

Abstract

BACKGROUND: The health status of employees with chronic hepatitis C has major implications for organizations and labour market.

OBJECTIVES: To assess the effects of Acetyl-L-Carnitine administration on work productivity, daily activity, and fatigue in subjects with chronic hepatitis C treated with Pegylated-Interferon-α2b and Ribavirin.

PATIENTS AND METHODS: In this prospective, randomized, placebo controlled, double blind clinical trial, 30 subjects (Group A) with chronic hepatitis, received Pegylated-Interferon-α2b (1.5 mg/kg per week) plus Ribavirin and placebo, while 32 subjects (Group B) received the same dosage of Pegylated-Interferon-α2b plus Ribavirin plus 2g Acetyl-L-Carnitine twice per day, for 12 months. Work productivity loss, impairment in daily activities, presenteeism, absenteeism, have been assessed using the Work Productivity and Activity Impairment questionnaire. We also evaluated severity of fatigue, mental fatigue and physical fatigue.

RESULTS: Significant difference were observed in physical fatigue, mental fatigue and severity of fatigue, aspartate aminotransferase, alanine aminotransferase, and viremia after 12 months treatment. In Group B we observed a significant decrease of presenteeism and daily activity impairment after 6 months, 12 months and at follow up. A significant increase of work productivity was observed after 12 months and at follow up.

CONCLUSIONS: Office workers with chronic hepatitis C, treated with Pegylated-Interferon-α2b plus Ribavirin, had work performance loss. In subjects treated with Acetyl-L-Carnitine supplementation we observed increased daily activity and reduced presenteeism and fatigue. Acetyl-L-Carnitinegroup had a smaller reduction of productivity comparing to placebo group.

Keywords: Acetyl Lcarnitine; Fatigue; Hepatitis C; Interferon; Quality of Life; Ribavirin

References

  1. J Psychosom Res. 2012 Sep;73(3):218-24 - PubMed
  2. J Hepatol. 2012 Dec;57(6):1379-90 - PubMed
  3. J Viral Hepat. 2009 Sep;16(9):605-11 - PubMed
  4. Curr Opin Gastroenterol. 2012 Mar;28(2):166-76 - PubMed
  5. J Interferon Cytokine Res. 2001 May;21(5):273-8 - PubMed
  6. J Interferon Cytokine Res. 2011 Sep;31(9):653-9 - PubMed
  7. Ann Intern Med. 2006 May 16;144(10):705-14 - PubMed
  8. JAMA. 1997 Mar 19;277(11):925-6 - PubMed
  9. Scand J Gastroenterol. 2011 Jun;46(6):750-9 - PubMed
  10. Value Health. 2002 Mar-Apr;5(2):106-13 - PubMed
  11. Curr Top Med Chem. 2013;13(15):1853-63 - PubMed
  12. Hepatology. 1996 Aug;24(2):289-93 - PubMed
  13. Arch Neurol. 1989 Oct;46(10):1121-3 - PubMed
  14. FASEB J. 1992 Dec;6(15):3379-86 - PubMed
  15. J Interferon Cytokine Res. 2008 Oct;28(10):603-9 - PubMed
  16. Metab Brain Dis. 2013 Jun;28(2):193-9 - PubMed
  17. Hepat Mon. 2013 Jan;13(1):e8340 - PubMed
  18. J Viral Hepat. 2002 Jul;9(4):295-303 - PubMed
  19. Hepatol Res. 2004 Jul;29(3):129-135 - PubMed
  20. Hepatology. 1994 May;19(5):1321-4 - PubMed
  21. Lancet. 2001 Sep 22;358(9286):958-65 - PubMed
  22. World J Gastroenterol. 2011 Oct 21;17(39):4414-20 - PubMed
  23. Hepatology. 2005 Apr;41(4):790-800 - PubMed
  24. Aliment Pharmacol Ther. 2004 Aug 15;20(4):459-67 - PubMed
  25. J Clin Microbiol. 1996 Sep;34(9):2259-66 - PubMed
  26. Hepatology. 1981 Sep-Oct;1(5):431-5 - PubMed
  27. J Neurol Neurosurg Psychiatry. 1989 Aug;52(8):940-8 - PubMed

Publication Types